These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27920051)

  • 1. Chimeric Antigen Receptor T-Cell Therapies Advancing.
    Brower V
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27920051
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors.
    Harris DT; Kranz DM
    Trends Pharmacol Sci; 2016 Mar; 37(3):220-230. PubMed ID: 26705086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
    Luo C; Wei J; Han W
    Sci China Life Sci; 2016 Apr; 59(4):349-59. PubMed ID: 27009301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy with T cells bearing chimeric antitumor receptors.
    Paillard F
    Hum Gene Ther; 1999 Jan; 10(2):151-3. PubMed ID: 10022540
    [No Abstract]   [Full Text] [Related]  

  • 9. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CART trials are going ahead.
    Wei J; Han W
    Sci China Life Sci; 2017 Nov; 60(11):1276-1279. PubMed ID: 29170890
    [No Abstract]   [Full Text] [Related]  

  • 11. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
    Han EQ; Li XL; Wang CR; Li TF; Han SY
    J Hematol Oncol; 2013 Jul; 6():47. PubMed ID: 23829929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T-cell therapy: opportunities and challenges.
    Zhang W
    Immunotherapy; 2016; 8(3):245-7. PubMed ID: 26860858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.
    Hombach A; Pohl C; Reinhold U; Abken H
    Hybridoma; 1999 Feb; 18(1):57-61. PubMed ID: 10211789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safer CARS.
    Heslop HE
    Mol Ther; 2010 Apr; 18(4):661-2. PubMed ID: 20357776
    [No Abstract]   [Full Text] [Related]  

  • 15. Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.
    Liu L; Sun M; Wang Z
    Cancer Lett; 2012 Mar; 316(1):1-5. PubMed ID: 22099879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles.
    Li K; Lan Y; Wang J; Liu L
    Tumour Biol; 2017 Mar; 39(3):1010428317692229. PubMed ID: 28347250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer.
    Hombach AA; Abken H
    Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616
    [No Abstract]   [Full Text] [Related]  

  • 20. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.